APOGEPHA International
With the development of a drug for the treatment of urinary incontinence (active ingredient: propiverine), APOGEPHA is one of the most important companies in the global market for urological spasmolytics.
![[Translate to English:] Zwei Mitarbeiter von APOGEPHA lächeln freundlich.](/fileadmin/_processed_/e/a/csm_csm_mandel-beier-web_6af29e6df9_e53b17fe6d.png)
APOGEPHA: important player in the field of urology
APOGEPHA is an independent, German, medium-sized pharmaceutical company.
We developed Propiverine, one of the leading medications for the treatment of overactive bladder and neurogenic detrusor overactivity in adults and children. Currently, the drug is available in more than 25 countries worldwide.
Various dosages and formulations of Propiverine are marketed under the brand names Mictonorm®, Mictoryl®, and Detrunorm®.
The unique once-daily Propiverine formulation, Mictonorm Uno®, is also approved in most countries. Currently, we have marketing and distribution partners in more than 25 countries, with a focus on Europe and Asia.
We are looking for licensing partners with expertise in urology in all promising markets.
Log-in for sales partners
Dear Partner,
Enjoy looking through the papers, marketing materials and presentations of the other partners of our Propiverine-family. There will certainly be a lot of good and exciting things to be found for local adaptation.
Your APOGEPHA-Team
Global partner network
Feel free to contact us if you are interested in a partnership in countries that have not yet been assigned.